Glenn S. Kerner

Glenn Kerner has deep experience in products liability law, particularly with respect to complex mass torts and multi-district litigation (MDL). Glenn has played a major role in some of the most notable mass torts and MDLs over the past 25 years. He also frequently litigates consumer class actions, individual cases, and acts as lead trial counsel in cases across multiple industries and jurisdictions. He represents clients in matters involving pharmaceuticals and medical devices, food and dietary supplements, emerging technologies, cannabis, and other consumer products.

Glenn regularly serves as lead counsel and has been appointed as liaison counsel in various mass tort litigations and MDLs. Most recently, Glenn has served as national counsel for a large generic pharmaceutical company in nearly 500 cases involving the cardiac drug amiodarone in Northern California, and throughout the country. He has also served as national counsel in numerous mass torts and MDLs including those involving ceramic hip devices, alendronate, metoclopramide, natural rubber latex gloves, orthopedic bone screws, pamidronate, propofol, PPA, semiconductor clean rooms, the diet drug fen-phen and ephedra. He works closely with a national network of medical, scientific, regulatory, and industry experts in preparation for trials and Daubert hearings.

Additionally, Glenn has experience in complex commercial litigation, antitrust, real estate litigation, and other civil litigation.

In addition to his litigation practice, Glenn provides strategic counseling to clients on litigation avoidance, litigation preparedness, and risk assessment. He also advises clients on labeling and warnings issues, including regulatory compliance.

Recognized as a thought leader in mass torts, pharmaceutical and medical device litigation, and other consumer products related law, Glenn is a frequent speaker on emerging issues on these topics. More recently, he was the co-author of “Introduction to Biosimilars and Labeling Issues” in For the Defense, a contributor to “Guide to Biosimilars Litigation and Regulation in the U.S.,” published by Thomas Reuters, and he wrote “Mobile Medical Apps: Understanding and Defending Against Product Liability Challenges” for DRI’s Rx For the Defense. In addition, Glenn has presented during multiple conferences and workshops including for the American Bar Association (ABA), the Defense Research Institute (DRI), and the American Conference Institute (ACI).

Concentrations

•Products liability law
•Complex mass torts and multi-district litigation (MDL)
•Consumer class actions
•Pharmaceuticals and medical devices

The attorney is providing legal services through and affiliated with Greenberg Traurig, LLP, a New York Limited Liability Partnership. Prior results do not guarantee a similar outcome.

Recognition & Leadership

Awards & Accolades

•Team Member, BTI’s Most Recommended Law Firms, Big Pharma, 2025
•Listed, Benchmark Litigation, “Litigation Star - Product Liability,” 2021-2026
•Recommended, Lexology Index, Product Liability Defence, 2025
•Team Member, a Law360 “Product Liability Practice Group of the Year,” 2021-2022
•Listed, Chambers USA, “Nationwide: Product Liability & Mass Torts,” 2015-2025
•Listed, The Legal 500, 2012-2024
•Listed, Best Lawyers in America, 2018-2026
•Mass Tort Litigation / Class Action - Defendants, 2018-2026
•'Lawyer of the Year,' Mass Tort Litigation / Class Action - Defendants, New York City, 2023 and 2025
•Product Liability Litigation - Defendants, 2018-2026
•Listed, Super Lawyers magazine, New York Metro Super Lawyers, 2009-2012, 2014-2025